Pharmaceutical Business review

Exelixis announces closure of public offering

The company also granted the underwriter a 30-day option to purchase up to an additional 1.05 million shares of common stock. Goldman, Sachs & Company acted as the sole underwriter for the offering.

The offering is being made pursuant to an effective automatic shelf registration statement.